Skip to main content
Premium Trial:

Request an Annual Quote

UgenTec, MDxHealth Partner To Develop AI Software for Prostate Cancer Tests

NEW YORK (GenomeWeb) – UgenTec announced today a partnership to develop artificially intelligent software to support interpretation of molecular test results for MDxHealth's ConfirmMDx and SelectMDx for prostate cancer tests.

MDxHealth's SelectMDx test is a liquid biopsy test that identifies patients with an increased risk for clinically significant prostate cancer. The firm's ConfirmMDx is a tissue biopsy test that allows patients to forgo unnecessary repeat biopsy procedures.

"[This automation step] will… also provide our SelectMDx IVD customers with an advanced software they can use [to] support and standardize drafting of result reports," MDxHealth CEO Jan Groen said in a statement.

Financial and other terms of the agreement were not disclosed.

In December, UgenTec expanded a collaboration with Fast Track Diagnostics to include artificially intelligent PCR software on FTR's kits.